Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy
September 19, 2025
- Lilly Japan Adds Tablet Formulation for Retevmo
September 19, 2025
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- Eisai’s Etalanetug Snags FDA Fast Track Designation
September 18, 2025
- Daito Wins China Approval for Celecoxib, 2nd Generic in Market
September 18, 2025
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
- Kyorin/aTyr’s Efzofitimod Misses Primary Goal in Global PIII Trial
September 17, 2025
- Mitsubishi, J&J to End Stelara Co-Promotion in Japan at Year-End
September 17, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- Daiichi Bags FDA Breakthrough Therapy Status for Anti-CDH6 ADC
September 17, 2025
- AbbVie Japan Seeks Rinvoq Label Expansion for Polyarticular JIA
September 16, 2025
- Clenafin Authorized Generic Hits Japan Market: Kaken
September 16, 2025
- Lilly Confirms Safety of Oral GLP-1 Orforglipron in Japan PIII
September 16, 2025
- Pfizer’s Ulcerative Colitis Drug Velsipity Now Available in Japan
September 16, 2025
- Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
- Eisai Sees “Best-in-Class” Promise for E2086 as Once-Daily Narcolepsy Drug
September 12, 2025
- LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
- Enhertu’s Tumor-Agnostic Use Now under EU Review: Daiichi Sankyo
September 12, 2025
- Sawai, Nichi-Iko to Consolidate 15 APIs as Sector Tackles Small-Lot Production
September 11, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…